Alya Red is a virtual human that employs machine learning algorithms to analyze individual health data and create personalized medical treatment plans. This technology aims to enhance treatment efficacy and improve patient outcomes, ultimately increasing patients' longevity.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of predicting the outcomes of pharmacological and medical device treatments are often time-consuming, expensive, and may not fully represent the diversity of patient populations. This can lead to delays in bringing new therapies to market and potentially limit their effectiveness across different patient subgroups.
Solution
ELEM Biotech offers a virtual human simulation platform that creates diverse virtual populations to predict the efficacy of pharmaceutical and medical device therapeutics. By using supercomputers, ELEM generates virtual versions of individuals that mirror the diversity and pathologies of real-world populations. Pharmaceutical, MedTech companies, and CROs can leverage these in-silico trials to test products from the discovery phase through pre-clinical and clinical stages, optimizing drug delivery and assessing cardiac safety.
Target Audience
The primary customers are pharmaceutical and MedTech companies, as well as contract research organizations (CROs), seeking to enhance their testing and prediction accuracy in drug and medical device development.
Features
- Cloud-deployed platform utilizing supercomputing power for biomedical simulations.
- Virtual human models that evolve to reflect the diversity and pathologies of society.
- In-silico trials for testing products across various stages of development.
- Optimized drug delivery modeling.
- Cardiac safety assessment capabilities.